Search

Bitter vetch (Vicia ervilia (L.) Willd.), a grain legume crop well adapted in marginal soils, has mainly been used for animal feed. Nowadays, bitter vetch seeds in feed formulations are replaced by other protein sources such as soybean meal. However, in the context of sustainable economic development, it may be beneficial to enhance the cultivation of bitter vetch landraces in marginal areas. Fifty-six bitter vetch accessions of different provenance were preliminarily characterised by microsatellite DNA analysis to discriminate landraces suitable for specific and restricted environments. Twenty-two landraces of two genetically different groups were then selected for further characterisation by agro-morphological analyses. Being late-flowering with a seed yield of up to 3–4 t ha–1 in experimental field conditions, with neither chemical nor water input, these plants will be valuable material for long-term study to develop new cultivars adapted for seed production under organic agricultural systems in Southern Europe. The seeds of these 22 landraces were also evaluated, with positive results, as partial replacement of soybean in rabbit diets.

Dihydroquinidine (DQ) is contained in substantial amounts in quinidine salts, but its direct antiarrhythmic action has not been studied. The efficacy of oral DQ (300 mg t. i. d.) compared to disopyramide (D) (200 mg t.i.d.) was thus investigated using a double-blind crossover placebo-controlled protocol in 12 patients, aged 13 to 67 years, with chronic stable high frequency premature ventricular beats (PVB), defined as greater than 100 PVB/h during 48-72-h control Holter monitoring. The protocol included three 72-h treatment periods: DQ, D, and placebo at random. On days 2 and 3 of each period a 24-h Holter recording was carried out; drug blood levels were determined at peak (days 2 and 3) and trough time (day 3). No significant difference in the mean PVB/h was found between control (735 +/- 400) and placebo periods (564 +/- 388), or between the two Holter recordings of each period. Compared to placebo both DQ (106 +/- 113, p less than 0.005) and D (240 +/- 263, p less than 0.05) reduced the mean PVB/h, but the decrease was significantly higher with DQ (78 versus 53%, p less than 0.02). Nine patients (75%) on DQ and 5 (42%) on D had a greater than 70% decrease in mean PVB/h; complex PVBs were abolished in 3 of 6 patients on both treatments. On day 3, DQ plasma levels were 1.31 +/- 0.44 (peak) and 0.92 +/- 0.45 (trough) mg/l; D plasma levels were 2.88 +/- 0.64 (peak) and 2.02 +/- 0.31 (trough) mg/l; no significant difference was found between day 2 and day 3 samples.(ABSTRACT TRUNCATED AT 250 WORDS)